Osteoporosis Screen for Praja 1 E3 Ligase Inhibitors

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$149,800.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43AG025568-01
Award Id:
71092
Agency Tracking Number:
AG025568
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
271 GREAT VALLEY PARKWAY, SUITE 300, MALVERN, PA, 19355
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
MICHAEL MATTERN
(610) 644-6974
mattern@progenra.com
Business Contact:
(610) 644-6974
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): 0steoporosis represents a major challenge to the maintenance of health and quality of life in an aging population. Among the most promising and least exploited therapeutic interventions are those treatments designed to increase bone density. The selection and validation of targets that can be manipulated to achieve this anabolic effect depends on an increasing amount of information relating to bone formation. A novel area for drug discovery - protein homeostatic regulation via ubiquitin pathway enzymes -- has recently been demonstrated to have relevance to the search for anabolic osteoporosis drugs. Prajal, a RING-finger E3 ubiquitin ligase, has been found to catalyse ubiquitination and, subsequently, induce proteasomal degradation of Dlxin-1, a coactivator of the transcriptional activator DIx5. DIx5 is associated with programmed bone formation. Thus, selective inhibitors of this E3 ligase are hypothesized to increase bone density. In Phase I, it is proposed to establish a yeast-based screening assay for inhibitors of Prajal. Essential components of the E3 system (Prajal) will be cloned and expressed in S. cerevisiae, along with human Dlxin-1 linked to p53, and a reporter construct that monitors p53 activity (beta-galactosidase activation). The reconstructed E3 ligase function and reporter system will then be configured and validated as a high throughput screen for inhibitors of Prajal-mediated Dlxin-1 ubiquitination. Collections of plant and marine organism extracts, along with a small compound collection, will be screened for potent inhibitors of Prajal E3 ubiquitin ligase activity. In Phase II, fractionation of active extracts will be guided by the assay, to identify active principles. Novel pure compounds arising from this effort will be considered as development candidates for osteoporosis. The modular assay construction format will permit evaluation of other E3s that are associated with a variety of diseases.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government